logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > Pharmaceutical Intermediates > (3R,4R)-N,4-Dimethyl-1-(phenylmethyl)-3-piperidinamine Hydrochloride CAS 1062580-52-2

(3R,4R)-N,4-Dimethyl-1-(phenylmethyl)-3-piperidinamine Hydrochloride CAS 1062580-52-2

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 1062580-52-2

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15 days

Payment Terms: T/T, L/C, D/A, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
1062580-52-2
Appearance::
White Powder
Molecular Formula::
C14H24Cl2N2
Molecular Weight::
291.26000
EINECS NO::
700-696-2
MDL NO::
MFCD11044501
CAS NO::
1062580-52-2
Appearance::
White Powder
Molecular Formula::
C14H24Cl2N2
Molecular Weight::
291.26000
EINECS NO::
700-696-2
MDL NO::
MFCD11044501
(3R,4R)-N,4-Dimethyl-1-(phenylmethyl)-3-piperidinamine Hydrochloride CAS 1062580-52-2

Product Description:

Product Name: (3R,4R)-N,4-Dimethyl-1-(phenylmethyl)-3-piperidinamine hydrochloride CAS NO: 1062580-52-2

 

 

Synonyms:

cis-n-benzyl-3-methylamino-4-methyl-piperidi-ne dihydrochloride;

cis-n-benzyl-3-methylamino-4-methyl-piperidi-ne bis(hydrochloride);

 

 

Chemical & Physical Properties:

Appearance: White powder

Assay :≥99.0%

Melting Point: 249~251℃

Solubility: H2O: ≥ 890 mg/Ml

 

 

Safety Information:

HS Code: 2933399090

Hazard Class: IRRITANT

 

 

(3R, 4R) -N, 4-dimethyl-1 - (phenylmethyl) -3-piperidamide hydrochloride is a related compound of tofacitinib and can be used to prepare selective inhibitors of Janus kinase 1. (3R,4R)-N, 4-Dimethyl-1 -(Phenylmethyl) -3-piperidamide hydrochloride is an organic synthesis intermediate and pharmaceutical intermediate. It is mainly used as an intermediate of tofamitinib in the laboratory development process and in the development process of Chemicalbook for pharmaceutical research. An intermediate for the active substance tofaitinib for the treatment of adult patients with moderate to severe rheumatoid arthritis who have inadequate or intolerant methotrexate response.

 

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.